Trial of Memantine for Cognitive Impairment in Multiple Sclerosis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00300716
Verified April 2007 by Oregon Health and Science University. Recruitment status was: Recruiting
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
A diagnosis of multiple sclerosis as defined by the McDonald criteria. Patients with relapsing-remitting, secondary progressive, and primary progressive forms of MS are eligible.
Age between 18 and 65 years.
Demonstrated cognitive dysfunction at screening defined as a score worse than 1.0 standard deviations below the mean on the PASAT or the CVLT-II.
A history of major depression, psychosis, or a score > 19 on the Beck's Depression Inventory.
Corrected binocular visual acuity worse than 20/50; any impairment of binocular color vision.
Patients that do not speak English as a primary language (fluency may impact performance).
A clinically significant MS exacerbation within 30 days of the screening
History of seizures.
Patients using acetazolamide (Diamox, Ak-sol, Storzolamide), dichlorphenamide (Daranide), methazolamide (Neptazane) or topiramate (Topamax), dextromethorphan (Robitussin DM and other cold remedies), or amantadine (Symmetrel).
Use of medical marijuana in the prior six months.
History of alcohol abuse or illicit drug use in the prior six months.